NEW YORK, Feb 8, 2026, 13:48 EST — Market closed
- Hims & Hers plans to drop its compounded semaglutide pill, following signals from U.S. regulators about tightening enforcement on copycat GLP-1 drugs.
- The Health Care Select Sector SPDR Fund (XLV) closed out Friday with a 1.9% gain, though that headline number hides some big swings among insurers and telehealth stocks.
- Traders are eyeing any sign that regulatory scrutiny might turn into lawsuits, and they’re listening closely to how managed-care companies describe their outlook for 2026 medical costs.
Hims & Hers announced Saturday it’s discontinuing access to its compounded semaglutide pill—previously sold at $49 a month—after U.S. regulators threatened enforcement on off-brand weight-loss treatments. Shares in Hims dropped 15.9% Friday, closing at $19.36. https://www.reuters.com/legal/litigation/hims-hers-stop-offering-compounded-semaglutide-pill-after-fda-crackdown-2026-02-07/ https://finance.yahoo.com/quote/HIMS/history/
The incident injects new regulatory uncertainty into a part of “healthcare stocks” that’s been buoyed by the surge in GLP-1 drug demand—these are diabetes and obesity treatments—while also sharpening the divide among their branded producers.
It comes as investors flip between defensive healthcare picks and fresh shocks in managed care, a space where swings in medical costs or government reimbursement rates can yank guidance around quickly.
The FDA said Friday it’s planning to crack down on GLP-1 active pharmaceutical ingredients used in “non-FDA-approved compounded drugs”—custom-mixed medicines that skip the agency’s typical approval path. “The FDA intends to take decisive steps to restrict” those GLP-1 ingredients, Commissioner Martin A. Makary said in a statement. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
The Health Care Select Sector SPDR Fund finished Friday up 1.85%, settling at $157.71. https://finance.yahoo.com/quote/XLV/history/
Regulators stepped up their scrutiny of GLP-1s right after Hims rolled out its new pill on Thursday—a move that pushed shares of leading weight-loss drugmakers lower that day. Some of those losses were clawed back on Friday. https://www.investopedia.com/hims-and-hers-launches-new-pill-that-sends-shockwaves-across-weight-loss-drugmakers-stocks-11900371
Molina Healthcare went the other way in managed care. The stock tanked over 28% on Friday after the company said its 2026 profit would come in at less than half of what analysts were looking for, and announced plans to pull out of Medicare Advantage prescription drug plans in 2027. “The imbalance between rates and trend marks 2026 as a trough year for Medicaid industry margins,” CEO Joseph Zubretsky told investors. https://www.reuters.com/business/healthcare-pharmaceuticals/molina-plunges-after-issuing-2026-profit-forecast-much-below-expectations-2026-02-06/
Healthcare heavyweights tracked the market higher on Friday, with insurers and services stocks notching notable moves. Investors focused on sorting out which companies faced their own cost headaches versus broader sector stress. https://www.marketwatch.com/data-news/cigna-group-stock-underperforms-friday-when-compared-to-competitors-despite-daily-gains-c1190a64-01ad3ead9c1b
Several drugmakers brought forward their own updates. Pfizer announced the FDA has accepted and granted Priority Review for a supplemental application tied to HYMPAVZI (marstacimab), with the agency expected to make its decision in the second quarter of 2026. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,” said Michael Vincent, Pfizer’s Chief Inflammation & Immunology Officer. (The PDUFA date marks the FDA’s target for a ruling.) https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-hympavzir-marstacimab-sbla
The focus now shifts to Monday’s open, where investors get their shot at reacting to the Hims reversal. It’s not just about weekend headlines. The bigger question: will regulators or the Justice Department act fast enough to shake up practices across telehealth and compounding?
Up next: CVS Health’s quarterly earnings, set to drop Tuesday at 8:00 a.m. ET. Investors are zeroed in on guidance, pharmacy benefit trends, and any signals on sector-wide medical costs. https://investors.cvshealth.com/events-and-presentations/event-details/2026/Q4-2025-Earnings-Conference-Call-2026-66crk8-NAH/default.aspx
